213 related articles for article (PubMed ID: 37283257)
1. Survival Outcomes of Post-mastectomy Breast Cancer Patients Treated with Hypofractionated Radiation Treatment Compared to Conventional Fractionation -a Retrospective Cohort Study.
Raveendran C; Meloot SS; Yadev I
Gulf J Oncolog; 2023 May; 1(42):26-34. PubMed ID: 37283257
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer.
Tovanabutra C; Katanyoo K; Uber P; Chomprasert K; Sukauichai S
Asian Pac J Cancer Prev; 2020 Jan; 21(1):119-125. PubMed ID: 31983173
[TBL] [Abstract][Full Text] [Related]
3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated Simultaneous Integrated Boost Radiotherapy Versus Conventional Fractionation Radiotherapy of Early Breast Cancer After Breast-Conserving Surgery: Clinical Observation and Analysis.
Dong J; Yang Y; Han D; Zhao Q; Liu C; Sun H; Wang Z; Lin H; Huang W
Technol Cancer Res Treat; 2021; 20():15330338211064719. PubMed ID: 34898315
[No Abstract] [Full Text] [Related]
5. HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.
Yadav BS; Dahiya D; Kannan P; Goyal S; Laroiya I; Irrinki S; Singh NR; Sharma R
Trials; 2024 Jan; 25(1):21. PubMed ID: 38167339
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of adjuvant proton radiotherapy for breast cancer after lumpectomy: a comparison of conventional-dose and hypofractionated dose.
Hong Z; Yang Z; Mei X; Li P; Bao C; Wang Z; Cai X; Ming X; Wang W; Guo X; Yu X; Zhang Q
Radiat Oncol; 2023 Mar; 18(1):56. PubMed ID: 36959653
[TBL] [Abstract][Full Text] [Related]
7. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Wang SL; Fang H; Song YW; Wang WH; Hu C; Liu YP; Jin J; Liu XF; Yu ZH; Ren H; Li N; Lu NN; Tang Y; Tang Y; Qi SN; Sun GY; Peng R; Li S; Chen B; Yang Y; Li YX
Lancet Oncol; 2019 Mar; 20(3):352-360. PubMed ID: 30711522
[TBL] [Abstract][Full Text] [Related]
9. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
Haviland JS; Owen JR; Dewar JA; Agrawal RK; Barrett J; Barrett-Lee PJ; Dobbs HJ; Hopwood P; Lawton PA; Magee BJ; Mills J; Simmons S; Sydenham MA; Venables K; Bliss JM; Yarnold JR;
Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
Murray Brunt A; Haviland JS; Wheatley DA; Sydenham MA; Alhasso A; Bloomfield DJ; Chan C; Churn M; Cleator S; Coles CE; Goodman A; Harnett A; Hopwood P; Kirby AM; Kirwan CC; Morris C; Nabi Z; Sawyer E; Somaiah N; Stones L; Syndikus I; Bliss JM; Yarnold JR;
Lancet; 2020 May; 395(10237):1613-1626. PubMed ID: 32580883
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity.
Deantonio L; Gambaro G; Beldì D; Masini L; Tunesi S; Magnani C; Krengli M
Radiat Oncol; 2010 Nov; 5():112. PubMed ID: 21092288
[TBL] [Abstract][Full Text] [Related]
12. Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.
Jain N; Sharma R; Sachdeva K; Kaur A; Sudan M
J Med Phys; 2022; 47(2):141-144. PubMed ID: 36212213
[TBL] [Abstract][Full Text] [Related]
13. Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.
Venigalla S; Guttmann DM; Jain V; Sharma S; Freedman GM; Shabason JE
Clin Breast Cancer; 2018 Oct; 18(5):e899-e908. PubMed ID: 29550285
[TBL] [Abstract][Full Text] [Related]
14. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
15. A Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast Cancer.
Lee SW; Kim YJ; Shin KH; Kim K; Chie EK; Han W; Im SA; Jung SY; Lee KS; Lee ES
Medicine (Baltimore); 2016 May; 95(19):e3320. PubMed ID: 27175630
[TBL] [Abstract][Full Text] [Related]
16. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
17. Update on Accelerated Whole Breast Irradiation.
Shah C; Fleming-Hall E; Asha W
Clin Breast Cancer; 2023 Apr; 23(3):237-240. PubMed ID: 36792457
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis.
Kim DY; Park E; Heo CY; Jin US; Kim EK; Han W; Shin KH; Kim IA
Breast; 2021 Feb; 55():37-44. PubMed ID: 33316582
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two hypofractionated radiotherapy schedules in locally advanced postmastectomy breast cancer patients.
Choudhary S; Gupta N; Misra S; Munnee NN; Kumar A; Ranjan R; Dhar SS; Kumar D; Mourya A; Aggarwal LM
J Cancer Res Ther; 2020; 16(6):1331-1335. PubMed ID: 33342792
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis on safety and effectiveness of hypofractioned post-mastectomy radiotherapy.
Bochenek-Cibor J; Georgiew F; Goyal S
Breast J; 2020 Feb; 26(2):176-181. PubMed ID: 31531930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
